Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

By N. Johnson, K. Savage, O. Ludkovski, S. Ben-Neriah, R. Woods, C. Steidl, M. Dyer, R. Siebert, J. Kuruvilla, R. Klasa and 3 more. Blood, 2009

615 citations recorded by the source corpus.

Subfields: Genetics, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/45e4e663d4931a170f1458dd140f6f2a074ee5ba

Citations in the corpus

• Double-hit B-cell lymphomas. (2011, neutral): “Snuderl et al14 2010‡‡ 20/20 (100) 3/20§§ (15) 64 (32-91) 18/19 (95) 18/18 (100) 10/17 (59) 5/11(45) 6/20 (30)¶ 17/20 (85) Tomita et al11 2009 27/27 (100) 4/23 (17) 51 (36-79) 22/23 (96) 25/27 (93) 15/23 (65) 2/23 (9) 15/23 (65) 20/23 (87)”
• MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. (2009, neutral): “Bone marrow 0 11 (9) .280 Testicular 2 ( 17 ) 3 (2) .013 Sinus 0 2 (1.6) .280 Gastrointestinal 2 (17) 19 (15) .911 Kidney 0 2 (1.6) .656 Liver 0 7 (6) .396”